Merck's Keytruda Shows Recurrence-free Survival In Resected High-Risk Stage II Melanoma

Merck & Co., Inc. (MRK) said that the first results from the Phase 3 KEYNOTE-716 trial, in which adjuvant treatment with the company's anti-PD-1 therapy Keytruda, showed a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS), the trial's primary endpoint, compared to placebo in patients with resected high-risk stage II melanoma.

At the first interim analysis, Keytruda reduced the risk of disease recurrence or death by 35% compared to placebo. Median RFS had not been reached for either group at the time of this analysis. After 14.4 months follow-up, 11.1% of patients on Keytruda had recurrence or died compared with 16.8% of patients on placebo, with fewer distant recurrences with Keytruda versus placebo.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Royal Caribbean Group's ultra-luxury brand Silversea Cruises is set to launch the world's first hybrid-powered cruise ship in the summer of 2023. This will also be the first ship with large-scale fuel cell technology to enable emission-free port operations. The fuel cells will provide 100% of power while at port. Affco USA is recalling around 24,461 pounds of frozen raw lamb shoulder products that were not presented for import re-inspection into the U.S., the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The recall involves the frozen raw lamb shoulder items that were imported on July 12, 2021. American Express Company (AXP) reported an increase in profit for the third quarter that also topped Wall Street estimates. Consolidated total revenues net of interest expense rose 25 percent year-on-year, primarily reflecting growth in Card Member spending, as well as a rise in the average discount...
Follow RTT